Lung cancer is the leading cause of cancer death in Taiwan and the world, and its treatment has always been a topic of concern in the country. A research team composed of Drs. Pan-Chyr Yang (Academician of Academia Sinica), Shu-Ping Wang (Assistant Research Fellow) and Chia-Sing Lu (Postdoctoral Fellow) of the Institute of Biomedical Sciences, found that the chemotherapeutic agent “Pemetrexed” can trigger the TS-ROS-NF-kB regulatory axis to activate the expression of PD-L1 in lung cancer cells, thereby creating a favorable tumor microenvironment for immunotherapy. The combined use of this chemotherapy and immunotherapy can become the first-line treatment for advanced lung cancer.

Link of Article: https://jitc.bmj.com/content/8/2/e001392